One of the more insidious facets of cancer is that,
for a variety of biochemical reasons, most cancers do not elicit an immune
response from the body. The human body’s immune system is well adept at
thwarting foreign cells and pathogens and is very capable of destroying many
cancer cells once activated. For this reason, there has been a great deal of
research in ‘immunotherapy’ which is effectively a process of vaccinating the
human body against cancer so that it recognizes and destroys cancer cells as though
they were pathogens. This provides for a much more selective therapy overall as
compared to conventional cytotoxic chemotherapies. Recently, researchers at
Dana Faber, Harvard Medical School, MIT, Howard Hughes Medical Institute, and Koch
Institute for Integrative Cancer Research utilized Mal-PEG-PLGA (Cat# AI053)
and PLGA (Cat # AP041) from PolySciTech (www.polyscitech.com)
to generate nanoparticles with reactive exteriors. These nanoparticles were
conjugated to targeting ligands via Michael’s reaction between the maleimide
units and thiol-bearing antibody fragments. The formed nanoparticles were found
to target immune cells and deliver immunotherapy agents to them. This research
holds promise for enhanced cancer therapy. Read more: Cartwright, A.N., Hartl,
C.A., Park, C.G., Schmid, D., Irvine, D.J., Freeman, G.J., Maiarana, J.,
Wucherpfennig, K.W., Goldberg, M.S., Subedi, N. and Puerto, R.B., 2017. T
cell-targeting nanoparticles focus delivery of immunotherapy to improve
antitumor immunity. Nature communications, 8, p.1747. https://www.nature.com/articles/s41467-017-01830-8
“Abstract: Targeted delivery of compounds to
particular cell subsets can enhance therapeutic index by concentrating their
action on the cells of interest. Because attempts to target tumors directly
have yielded limited benefit, we instead target endogenous immune cell subsets
in the circulation that can migrate actively into tumors. We describe
antibody-targeted nanoparticles that bind to CD8+ T cells in the blood,
lymphoid tissues, and tumors of mice. PD-1+ T cells are successfully targeted
in the circulation and tumor. The delivery of an inhibitor of TGFβ signaling to
PD-1-expressing cells extends the survival of tumor-bearing mice, whereas free
drugs have no effect at such doses. This modular platform also enables
PD-1-targeted delivery of a TLR7/8 agonist to the tumor microenvironment,
increasing the proportion of tumor-infiltrating CD8+ T cells and sensitizing
tumors to subsequent anti-PD-1. Targeted delivery of immunotherapy to defined
subsets of endogenous leukocytes may be superior to administration of free
drugs.”
No comments:
Post a Comment